Merck
  • Home
  • Search Results
  • Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma.

Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma.

Journal of clinical pharmacy and therapeutics (2014-11-22)
L Vadot, M Boulin, B Guiu, L S Aho, M Vourc'h, A Musat, P Hillon, C Lepage, M-H Guignard, P Fagnoni
ABSTRACT

Drug eluting beads (DEBs) theoretically improve the efficacy and safety of transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). Nonetheless, their economic profile has not been assessed. Our retrospective before/after study aimed to compare efficacy, safety and economic profile of two strategies of TACE without (Period 1) or with the possibility of using DEBs (Period 2). All HCC patients treated by TACE in our hospital between March 2006 and May 2013 were included. Economic analyses were performed from the French Public Health Insurance point of view according to the French Diagnosis-Related Group prospective payment system and from the analytic accountability. One hundred and sixty-one patients were included. Median time to treatment failure and overall survival were 13.1 and 23.8 months in Period 1 vs. 14.1 and 30.2 months in Period 2 (P = 0.45 and P = 0.40). Mean hospital durations and tariffs were 14.9 ± 7.7 days and € 11 472 ± 5901 in Period 1 vs. 12.4 ± 8.4 days and € 7654 ± 4625 in Period 2 (P = 0.03 and P < 10(-4) ). The possibility of using DEBs did not improve the prognosis in HCC patients treated by TACE. Nonetheless, it had a better medico-economic profile.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
四硫富瓦烯, 97%
碘克沙醇, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
依达比星 盐酸盐, solid